One of the key takeaways from BIO-Europe Spring 2020, which was held virtually March 23-27, was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field, according to Atlas Venture partner Bruce Booth.
Atomwise, a leader in using artificial intelligence for small-molecule discovery, and Bridge Biotherapeutics, a clinical-stage biotech company, announced a research collaboration to launch up to 13 small-molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
As healthcare companies increasingly target products towards tech-savvy consumers with the hope of impacting patient engagement and loyalty, they must also expertly navigate legal, compliance and regulatory guidelines for patient privacy.
Novacyt says the Franco-British biotech company can offer a coronavirus test that is faster than rival methods by focusing on a narrow sequence of DNA coding.
With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.
This guide explores the different sources of funding available to biotech startups and their relative merits, and how you should best utilize that funding at each stage of your research.
An international team of researchers led by the University of Manchester developed a new antiviral using natural glucose derivatives called cyclodextrins – a type of sugar – which shows promise in treating a broad range of viruses including herpes simplex, respiratory syncytial virus, hepatitis C, HIV and Zika virus.
In a first-of-its-kind effort, the Biotechnology Innovation Organization (BIO) conducted a survey that attempts to dive into diversity within the pharmaceutical and biotech industry.
In August 1963, the Rev. Martin Luther King delivered his famous “I Have a Dream” speech that called for equality among all people, regardless of their ethnicity, as well as a vision for a better America for all. While the noble dreams that King outlined on that hot day in Washington, D.C. so many years ago have unfortunately not yet been fully realized, there are other kinds of dreams that may be closer to being achieved, particularly in the area of new medications for serious diseases.